公开(公告)号：US20200148779A1

公开(公告)日：2020-05-14

申请号：US16495994

申请日：2018-05-24

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Suzanne J. SUCHARD

IPC: C07K16/28

Abstract: Modified IgG1 Fc domains having reduced binding to Fc-gamma-receptors are provided. Further provided are fusion polypeptides comprising a modified IgG1 Fc domain. An antibody polypeptide that specifically binds a human CD40 is provided, wherein the antibody polypeptides are fusions of a domain antibody (dAb) comprising a single VH domain and an Fc domain. The antibody polypeptides do not exhibit CD40 agonist activity, do not substantially activate immature dendritic cells, and have improved biophysical properties.

公开(公告)号：US20220348625A1

公开(公告)日：2022-11-03

申请号：US17663384

申请日：2022-05-13

Applicant: Bristol-Myers Squibb Company

Inventor： Mary STRUTHERS ,  Jonathan Harry DAVIS ,  Michael Louis DOYLE ,  Priyanka Apurva MADIA

IPC: C07K14/55 ,  A61K47/65 ,  A61P37/04 ,  C07K14/715 ,  C07K16/28 ,  A61K38/17 ,  C12N15/62 ,  A61K38/20

Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

公开(公告)号：US20190300592A1

公开(公告)日：2019-10-03

申请号：US16366838

申请日：2019-03-27

Applicant: Bristol-Myers Squibb Company

Inventor： Mary STRUTHERS ,  Jonathan Harry DAVIS ,  Michael Louis DOYLE ,  Priyanka Apurva MADIA

IPC: C07K14/55 ,  C07K14/715 ,  A61K47/65 ,  C07K16/28 ,  A61P37/04

Abstract: Disclosed herein are fusion proteins comprising: (a) a first polypeptide comprising Interleukin-2 (IL2); and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL2Rα), wherein IL2 or IL2Rα comprises at least one fewer glycosylation site compared to native IL2 or native IL2Rα. Methods of production and methods of therapeutic use of the fusion proteins are also disclosed.

公开(公告)号：US20220177596A1

公开(公告)日：2022-06-09

申请号：US17561529

申请日：2021-12-23

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Suzanne J. SUCHARD

IPC: C07K16/28 ,  A61K39/395

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20220153856A1

公开(公告)日：2022-05-19

申请号：US17588518

申请日：2022-01-31

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, JR. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  C07K16/46 ,  A61P37/00

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20240239909A1

公开(公告)日：2024-07-18

申请号：US18441998

申请日：2024-02-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, JR. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/68 ,  A61P37/00 ,  C07K16/46 ,  C12N15/63 ,  A61K39/00 ,  A61K45/06 ,  C07K14/705

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K47/68 ,  A61K47/6849 ,  A61P37/00 ,  C07K16/468 ,  C12N15/63 ,  A61K2039/505 ,  A61K45/06 ,  A61K47/6803 ,  C07K14/70578 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20220169742A1

公开(公告)日：2022-06-02

申请号：US17670223

申请日：2022-02-11

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, Jr. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  C07K16/46 ,  A61P37/00

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20220144962A1

公开(公告)日：2022-05-12

申请号：US17579468

申请日：2022-01-19

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, JR. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  C07K16/46 ,  A61P37/00

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20200157233A1

公开(公告)日：2020-05-21

申请号：US16686596

申请日：2019-11-18

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron YAMNIUK ,  Mary STRUTHERS ,  Stanley R. KRYSTEK, JR. ,  Akbar NAYEEM ,  Ginger RAKESTRAW

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20240325495A1

公开(公告)日：2024-10-03

申请号：US18251214

申请日：2021-10-29

Applicant: Bristol-Myers Squibb Company

Inventor： Alice L. WANG ,  Mary STRUTHERS ,  Kimberly MCGORMAN ,  Neelanjana RAY ,  Karen D. PRICE ,  Nidhi SHARDA ,  Eun Mi HUR ,  Priyanka Apurva MADIA

IPC: A61K38/20 ,  A61K31/573 ,  A61K38/17 ,  A61P37/06

CPC classification number: A61K38/2013 ,  A61K31/573 ,  A61K38/1793 ,  A61P37/06

Abstract: Disclosed herein are methods of treating a disease or disorder in a subject in need thereof, comprising administering to the subject one or more doses of an Interleukin-2 (IL2) fusion protein, wherein the dose is from about 0.1 mg to about 9 mg. Also disclosed herein are methods of treating a disease or disorder in a subject in need thereof, comprising administering to the subject an dose of an IL2 fusion protein, wherein the dose is greater than about 9 mg. The IL2 fusion proteins used in the methods disclosed herein comprise: (a) a first polypeptide comprising an IL2 polypeptide; and (b) a second polypeptide comprising an extracellular domain of an IL2 Receptor alpha (IL2R) polypeptide. In some aspects, the disease or disorder is an immune-mediated disease, such as systemic lupus erythematosus. In some aspects, the methods further administering a corticosteroid to the subject.